• +1-646-491-9876
    • +91-20-67278686

    Search

    Actinic (Solar) Keratosis - Pipeline Review, H1 2017

    Actinic (Solar) Keratosis - Pipeline Review, H1 2017

    • Report Code ID: RW0001767493
    • Category Pharmaceuticals
    • No. of Pages 64
    • Publication Month Apr-17
    • Publisher Name Global Markets Direct
    Actinic (Solar) Keratosis - Pipeline Review, H1 2017

    Summary

    Publisher's latest Pharmaceutical and Healthcare disease pipeline guide Actinic (Solar) Keratosis - Pipeline Review, H1 2017, provides an overview of the Actinic (Solar) Keratosis (Dermatology) pipeline landscape.

    An actinic keratosis, also known as a solar keratosis, is a scaly or crusty growth (lesion) . It most often appears on the bald scalp, face, ears, lips, backs of the hands and forearms, shoulders, neck or any other areas of the body frequently exposed to the sun. The signs and symptoms of an actinic keratosis include a hard, wart-like surface, patch or bump on the top layer of skin, itching or burning in the affected area and color as varied as pink, red or brown, or flesh-colored. The predisposing factors include age, sunny climate, history of frequent or intense sun exposure or sunburn, pale skin, red or blond hair, and blue or light-colored eyes and a weak immune system as a result of chemotherapy, chronic leukemia, AIDS or organ transplant medications.

    Report Highlights

    Publisher's Pharmaceutical and Healthcare latest pipeline guide Actinic (Solar) Keratosis - Pipeline Review, H1 2017, provides comprehensive information on the therapeutics under development for Actinic (Solar) Keratosis (Dermatology) , complete with analysis by stage of development, drug target, mechanism of action (MoA) , route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

    The Actinic (Solar) Keratosis (Dermatology) pipeline guide also reviews of key players involved in therapeutic development for Actinic (Solar) Keratosis and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, Preclinical, Discovery and Unknown stages are 3, 6, 1, 6, 1 and 3 respectively. Similarly, the Universities portfolio in Phase II stages comprises 1 molecules, respectively.

    Actinic (Solar) Keratosis (Dermatology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Publisher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

    Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

    Scope

    - The pipeline guide provides a snapshot of the global therapeutic landscape of Actinic (Solar) Keratosis (Dermatology) .
    - The pipeline guide reviews pipeline therapeutics for Actinic (Solar) Keratosis (Dermatology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
    - The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
    - The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
    - The pipeline guide reviews key companies involved in Actinic (Solar) Keratosis (Dermatology) therapeutics and enlists all their major and minor projects.
    - The pipeline guide evaluates Actinic (Solar) Keratosis (Dermatology) therapeutics based on mechanism of action (MoA) , drug target, route of administration (RoA) and molecule type.
    - The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
    - The pipeline guide reviews latest news related to pipeline therapeutics for Actinic (Solar) Keratosis (Dermatology)

    Reasons to buy

    - Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
    - Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
    - Find and recognize significant and varied types of therapeutics under development for Actinic (Solar) Keratosis (Dermatology) .
    - Classify potential new clients or partners in the target demographic.
    - Develop tactical initiatives by understanding the focus areas of leading companies.
    - Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
    - Formulate corrective measures for pipeline projects by understanding Actinic (Solar) Keratosis (Dermatology) pipeline depth and focus of Indication therapeutics.
    - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
    - Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
    Table of Contents
    List of Tables
    List of Figures
    Introduction
    Publisher Report Coverage
    Actinic (Solar) Keratosis - Overview
    Actinic (Solar) Keratosis - Therapeutics Development
    Pipeline Overview
    Pipeline by Companies
    Pipeline by Universities/Institutes
    Products under Development by Companies
    Products under Development by Universities/Institutes
    Actinic (Solar) Keratosis - Therapeutics Assessment
    Assessment by Target
    Assessment by Mechanism of Action
    Assessment by Route of Administration
    Assessment by Molecule Type
    Actinic (Solar) Keratosis - Companies Involved in Therapeutics Development
    3M Drug Delivery Systems
    Athenex Inc
    CritiTech Inc
    Foamix Pharmaceuticals Ltd
    G&E Herbal Biotechnology Co Ltd
    Galderma SA
    Laboratories Ojer Pharma SL
    LEO Pharma A/S
    Novartis AG
    Oncology Research International Ltd
    Promius Pharma LLC
    Valeant Pharmaceuticals International Inc
    Vectura Group Plc
    Actinic (Solar) Keratosis - Drug Profiles
    854-A - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    ACT-01 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    AD-17137 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    celecoxib - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    DFD-08 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    GDC-695 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    hydrogen peroxide + sulindac - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    IDP-125 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    IDP-128 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    imiquimod - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    imiquimod SR - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    ingenol disoxate - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    KX-01 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    LFX-453 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    ORIL-007 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    paclitaxel - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    resiquimod - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    SKP-024 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    Small Molecules to Activate Protein Kinase C for Actinic Keratosis and Non-melanoma Skin Cancer - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    SRT-100 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    VDA-1102 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    Actinic (Solar) Keratosis - Dormant Projects
    Actinic (Solar) Keratosis - Discontinued Products
    Actinic (Solar) Keratosis - Product Development Milestones
    Featured News & Press Releases
    Dec 12, 2016: Vidac Pharma Phase 2 Study Of VDA-1102 In Actinic Keratosis Meets Interim Analysis Criterion
    Jul 29, 2016: Vidac Pharma Announces The Innitiation Of A Phase 2 Study Of VDA-1102 Ointment In Patients With Actinic Keratosis
    Jun 30, 2016: Vidac Pharma Completes Phase 1A Trial Of VDA-1102 Ointment
    Feb 25, 2016: Vidac Pharma Initiates Phase I Clinical Trial With Its Novel VDAC/HK2 Modulator
    Dec 30, 2015: Vidac Pharma Announces Filing of IND with U.S. FDA for Development of VDA-1102 for Treatment of Actinic Keratosis
    Jan 20, 2015: Kinex Pharmaceuticals Announces First Patient Dosed with KX2-391 Ointment for Actinic Keratosis in a Phase 1 Clinical Study
    Appendix
    Methodology
    Coverage
    Secondary Research
    Primary Research
    Expert Panel Validation
    Contact Us
    Disclaimer

    List of Tables

    Number of Products under Development for Actinic (Solar) Keratosis, H1 2017
    Number of Products under Development by Companies, H1 2017
    Number of Products under Development by Universities/Institutes, H1 2017
    Products under Development by Companies, H1 2017
    Products under Development by Companies, H1 2017 (Contd..1) , H1 2017
    Products under Development by Universities/Institutes, H1 2017
    Number of Products by Stage and Target, H1 2017
    Number of Products by Stage and Mechanism of Action, H1 2017
    Number of Products by Stage and Route of Administration, H1 2017
    Number of Products by Stage and Molecule Type, H1 2017
    Actinic (Solar) Keratosis - Pipeline by 3M Drug Delivery Systems, H1 2017
    Actinic (Solar) Keratosis - Pipeline by Athenex Inc, H1 2017
    Actinic (Solar) Keratosis - Pipeline by CritiTech Inc, H1 2017
    Actinic (Solar) Keratosis - Pipeline by Foamix Pharmaceuticals Ltd, H1 2017
    Actinic (Solar) Keratosis - Pipeline by G&E Herbal Biotechnology Co Ltd, H1 2017
    Actinic (Solar) Keratosis - Pipeline by Galderma SA, H1 2017
    Actinic (Solar) Keratosis - Pipeline by Laboratories Ojer Pharma SL, H1 2017
    Actinic (Solar) Keratosis - Pipeline by LEO Pharma A/S, H1 2017
    Actinic (Solar) Keratosis - Pipeline by Novartis AG, H1 2017
    Actinic (Solar) Keratosis - Pipeline by Oncology Research International Ltd, H1 2017
    Actinic (Solar) Keratosis - Pipeline by Promius Pharma LLC, H1 2017
    Actinic (Solar) Keratosis - Pipeline by Valeant Pharmaceuticals International Inc, H1 2017
    Actinic (Solar) Keratosis - Pipeline by Vectura Group Plc, H1 2017
    Actinic (Solar) Keratosis - Dormant Projects, H1 2017
    Actinic (Solar) Keratosis - Dormant Projects, H1 2017 (Contd..1) , H1 2017
    Actinic (Solar) Keratosis - Discontinued Products, H1 2017

    List of Figures

    Number of Products under Development for Actinic (Solar) Keratosis, H1 2017
    Number of Products under Development by Companies, H1 2017
    Number of Products by Targets, H1 2017
    Number of Products by Stage and Targets, H1 2017
    Number of Products by Mechanism of Actions, H1 2017
    Number of Products by Stage and Top 10 Mechanism of Actions, H1 2017
    Number of Products by Routes of Administration, H1 2017
    Number of Products by Stage and Routes of Administration, H1 2017
    Number of Products by Stage and Molecule Types, H1 2017
    3M Drug Delivery Systems
    Athenex Inc
    CritiTech Inc
    Foamix Pharmaceuticals Ltd
    G&E Herbal Biotechnology Co Ltd
    Galderma SA
    Laboratories Ojer Pharma SL
    LEO Pharma A/S
    Novartis AG
    Oncology Research International Ltd
    Promius Pharma LLC
    Valeant Pharmaceuticals International Inc
    Vectura Group Plc

    Request for Sample

    Report Url http://www.reportsweb.com//actinic-solar-keratosis-pipeline-review-h1-2017&type=sample
    Report Name
    First Name
    Last Name
    Email
    Phone
    Company
    Job Title
    Country
    Publisher
    Report Code
    Comments
     

    Inquire before Buying

    Report Url http://www.reportsweb.com//actinic-solar-keratosis-pipeline-review-h1-2017&type=buying
    Report Name
    First Name
    Last Name
    Email
    Phone
    Company
    Job Title
    Country
    Publisher
    Report Code
    Comments
     

    Inquire for Discount

    Report Url http://www.reportsweb.com//actinic-solar-keratosis-pipeline-review-h1-2017&type=discount
    Report Name
    First Name
    Last Name
    Email
    Phone
    Company
    Job Title
    Country
    Publisher
    Report Code
    Comments